Dossier assessment
Axicabtagene ciloleucel (follicular lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Project details
- Project no.
- G22-40
- Commission
- Commission awarded on 15.11.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Withdrawn commission
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
Connected Projects
-
Dossier assessment
Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Axicabtagene ciloleucel (DLBCL and HGBL) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Withdrawn commission